Oculus Innovative Sciences has received an expanded label clearance from the FDA to market Microcyn Rx. The prescription product is indicated for use in managing the debridement of wounds such as stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first- and second-degree burns, as well as grafted and donor sites.

Microcyn is already available as an over-the-counter product, Microcyn OTC, for moistening absorbent wound dressings and cleaning minor cuts, minor burns, superficial abrasions, and minor skin irritations.

For more information call (888) 263-0620 or visit www.oculusis.com.